DR5 is overexpressed in various cancers, including liver cancer, melanoma, and pancreatic cancer, while its presence in normal tissues is significantly lower.[45, 46, 47] DR5 agonist scFv containing EV hybrids' binding affinity to DR5 were assessed using A375 melanoma cell lines with DR5 knockout (KO), wild type (WT), and overexpression (OExp). Here, TNFRSF10B is linked to familial pancreatic carcinoma.